NCT05451719尚未招募2 期
Efficacy and Safety of Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Treatment for Metastatic Colorectal Cancer After First-line Chemotherapy: A Phase II, Randomized, Controlled Study
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 116
- 主要终点
- Progression-free Survival (PFS)
研究概览
简要总结
This is an open-label, multicenter, randomized phase 2 study evaluating the efficacy and safety of fruquintinib plus capecitabine versus capecitabine as maintenance therapy for metastatic colorectal cancer after first-line treatment. Patients who have already achieved disease control (including CR/PR and SD) after ≥6 cycles of standard first-line induction treatment, and are still unresectable would be assigned into 2 maintenance treatment groups by randomization in a 1:1 ratio to receive fruquintinib + capecitabine or capecitabine. All patients will be treated until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18 years old at the time of signing the informed consent;
- •Patients who have been histologically or cytologically confirmed adenocarcinoma of the colon or rectum (stage IV);
- •Patients who have achieved disease control (including CR/PR and SD) after 6 cycles of first-line standard chemotherapy and are still unresectable;
- •At least one measurable metastatic lesion(s) as defined by RECIST version 1.1;
- •ECOG performance status of 0-2;
- •Life expectancy≥3 months;
- •Adequate organ and bone marrow functions: Neutrophils >1.5×109/L, platelets >100×109/L, and hemoglobin >9 g/dL; Total bilirubin <1.5×upper limit of normal (ULN); aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and/or alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) <3×ULN (<5×ULN in case of liver metastases); Creatinine clearance (calculated according to Cockcroft and Gault) ≥60 mL/min; Serum creatinine < 1.5×ULN;
- •Women of childbearing age must have a negative pregnancy test within the first day of the study, and contraceptive methods should be taken during the study until 6 months after the last administration;
- •Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure.
排除标准
- •Had a surgical procedure within 4 weeks prior to treatment; Received radiation therapy, radiofrequency therapy, chemotherapy, immunotherapy or molecular targeted therapy, or other investigational drugs within 2 weeks prior to treatment;
- •Prior treatment with anti-vascular small-molecule targeted drugs, such as Fruquintinib or Regorafenib;
- •A history of severe intolerance to capecitabine or 5-FU (i.e. grade 4 toxicity of one of the drugs; Grade 3-4 toxicity of other concomitant drugs is not excluded);
- •Symptomatic brain or meningeal metastases (except for patients with BMS who have received local radiotherapy or surgery for more than 6 months and whose disease is stable).
- •Patients with hypertension that cannot be well controlled by antihypertensive medication (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg);
- •Have obvious clinical bleeding symptoms or obvious bleeding tendency within 3 months before treatment (bleeding > 30 mL within 3 months, hematemesis, black feces, hematozoia), hemoptysis (fresh blood > 5 mL within 4 weeks), etc. Treatment for venous/venous thrombosis events within the previous 6 months, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism; Long-term anticoagulant therapy with warfarin or heparin, or long-term antiplatelet therapy (aspirin ≥300 mg/day or clopidogrel ≥75 mg/day);
- •Active heart disease, including myocardial infarction, severe/unstable angina, 6 months prior to treatment. Echocardiography examination left ventricular ejection fraction < 50%, arrhythmia control is not good;
- •The patient has had other malignant tumors within 3 years (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
- •Allergy to the study drug or any of its excipients;
- •Severe infection with active or uncontrolled infection;
- •Any other disease, with clinical significance of metabolic abnormalities, abnormal physical examination or laboratory abnormalities, according to researchers, there is reason to suspect the patient has not suitable for the use of study drugs of a disease or condition (such as have a seizure and require treatment), or will affect the interpretation of results, or to make patients in high-risk situations;
- •Urine routine showed urine protein ≥2+, and 24-hour urine protein level >1.0g.
研究组 & 干预措施
Fruquintinib Plus Capecitabine
Experimental
Maintenance therapy with Fruquintinib Plus Capecitabine
干预措施: Fruquintinib Plus Capecitabine (Drug)
Capecitabine
Active Comparator
Maintenance therapy with Capecitabine
干预措施: Capecitabine (Drug)
结局指标
主要结局
Progression-free Survival (PFS)
时间窗: From Baseline to primary completion date, about 24 months
A duration from the date of initial treatment to disease progression or death of any cause
次要结局
- Objective response rate (ORR, RECIST 1.1)(From Baseline to primary completion date, about 24 months)
- Disease Control Rate (DCR, RECIST 1.1)(From Baseline to primary completion date, about 24 months)
- Overall survival (OS)(From Baseline to primary completion date, about 24 months)
- The incidence of adverse events(From Baseline to primary completion date, about 24 months)
研究者
Junjie Peng
Chief Physician
Fudan University
相似试验
招募中
2 期
The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal CancerMetastatic Colorectal CancerNCT05555901Fudan University116
招募中
2 期
Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal CancerMetastatic Colorectal CancerNCT05659290Nanfang Hospital, Southern Medical University40
招募中
不适用
Fruquintinib Combined With TAS102 for Advanced Gastric CancerGastric CancerNCT06102785Tianjin Medical University Cancer Institute and Hospital30
Unknown
2 期
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer PatientsPancreatic CancerNCT05168527Fudan University30
Unknown
1 期
Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal CancerMetastatic Colorectal CancerNCT05016869Chinese Academy of Medical Sciences48